Background: A reproducible standard for a graded allergen response in allergic rhinitis is lacking. The aim was to evaluate basophil allergen threshold sensitivity, CD-sens, as a diagnostic complement to nasal allergen challenge. Methods: Twenty-six patients with a history of allergic rhinitis due to grass pollen were intranasally challenged and nasal symptom score and peak nasal inspiratory flow (PNIF) changes were determined after 15 min. A 20% decrease in PNIF or a symptom score ≥2 were considered a positive test. A blood sample for CD-sens was drawn before each challenge. Eighteen patients were tested twice. Results: CD-sens agreed with the positive or negative nasal symptom score in 22/26 and PNIF in 24/26 patients. After the second challenge, 14/18 patients had the same symptom, 17/18 the same PNIF, while all had identical CD-sens classification. Conclusion: CD-sens appears to be a reproducible test for diagnosis of allergic rhinitis with great advantages also for follow-up of disease development and treatment effects.

1.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic rhinitis and its impact on asthma (ARIA). 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(suppl 86):8–160.
2.
Vohlonen I, Terho EO, Koivikko A, Vano T, Holmen A, Heinonen OP: Reproducibility of the skin prick test. Allergy 1989;44:525–531.
3.
Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R, et al: Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006;61:298–302.
4.
Johansson SGO, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, Söderström L, Stiller V, Öman H: Passive IgE-sensitization by blood transfusion. Allergy 2005;60:1192–1199.
5.
Andersson M, Greiff L, Svensson C, Persson C: Various methods for testing nasal responses in vivo: a critical review. Acta Otolaryngol 1995;115:705–713.
6.
Holmstrom M, Scadding GK, Lund VJ: The assessment of nasal obstruction – a comparison between rhinomanometry and nasal inspiratory peak flow. Rhinology 1990;28:191–196.
7.
Dahlen B, Nopp A, Johansson SGO, Eduards M, Skedinger M, Adédoyin J: Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma. Clin Exp Allergy 2011;41:1091–1097.
8.
Glaumann S, Nopp A, Johansson SGO, Rudengren M, Borres MP, Nilsson C: Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children. Allergy 2011;67:242–247.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.